ProGen Search

De-Risking Regulatory Submissions:

Lessons from 202 FDA CRLs

A Quantitative & Strategic Analysis of FDA Complete Response Letters

Prepared by

Byron Fitzgerald

Founder, ProGen Search

www.progensearch.com

ProGen Search partners with investors and leadership teams across Biotech, Pharma, CDMO, and CRO sectors to solve their most critical executive hiring challenges and build leadership teams that scale innovation. We were founded on the belief that executive search should be transparent, research-led, and deeply aligned to the future ambitions of the companies we serve.

Our story began from first-hand frustration with the traditional search model - one that often relied on opacity rather than insight. After 14 years in executive search - including scaling a consultancy to 36 consultants and refining an industry-leading model as co-founder of a specialist firm - ProGen's founder launched the business in December 2024 to deliver a more rigorous, open-source approach to leadership hiring.

Today, our clients trust us globally to identify, engage, and secure transformative talent - supported by deep sector research, transparent processes, and clear deliverables. Whether supporting scale-up biotech, investor-backed CDMOs, or emerging therapeutic platforms, we partner with clients not just to fill roles, but to shape the leadership needed to create long-term value.

Disclaimer

This report is provided for informational purposes only and does not constitute investment, financial, regulatory, or strategic advice. The content has been independently synthesized from publicly available sources, including the 202 Complete Response Letters (CRLs) released by the U.S. Food and Drug Administration as of July 2025.

While every effort has been made to ensure the accuracy and relevance of the information presented, no representations or warranties, express or implied, are made regarding the completeness, reliability, or suitability of this material for any particular purpose. The views and interpretations contained herein reflect ProGen Search's understanding at the time of publication and are subject to change.

Readers should conduct their own due diligence and consult with qualified professionals before making any decisions based on this report. ProGen Search accepts no liability for any loss or damage arising from the use of this document or its contents.

Anatomy of a Complete Response Letter: A Quantitative & Strategic Analysis of 202 FDA Rejections

Chapter 1: Executive Summary: The Execution Imperative

A ProGen Search analysis of 202 Complete Response Letters (CRLs) issued by the U.S. Food and Drug Administration reveals a critical insight for the biopharmaceutical industry: the primary obstacles to drug approval are often not rooted in scientific discovery but in fundamental failures of operational execution. While clinical data provides the rationale for a product's existence, our findings show that 74% of all CRLs cited at least one major deficiency in Chemistry, Manufacturing, and Controls (CMC), making it the most significant and frequent domain of failure.

The financial and strategic implications of a CRL are substantial, often resulting in launch delays of 12-24 months, significant unplanned expenditure for remediation and new studies, and a loss of investor confidence. This report provides a quantitative and qualitative assessment of these failures to equip sponsors with a data-driven framework for de-risking their regulatory submissions. Our analysis identified three principal domains of deficiency:

- Manufacturing & Product Quality (74% of CRLs): The dominant failure category, driven by unresolved facility inspection findings (58%), inadequate control over product impurities and container leachables (28%), and insufficient stability data (19%). This highlights a critical and costly gap between product development and scaled, compliant manufacturing.
- Clinical Evidence & Strategy (35% of CRLs): Deficiencies in this area stemmed from a failure to provide "substantial evidence of effectiveness." Key drivers included failed primary endpoints (16%) and clinically insignificant treatment effects (9%), underscoring the risk of misalignment between trial design and regulatory expectations for clinical relevance.
- Device & User Interface Integration (18% of CRLs): For combination products, flaws in the device component or its use were a significant hurdle. The most common issue was the failure of Human Factors (HF) validation studies, indicating that the product could not be used safely and effectively by its intended users.

This report will dissect each of these themes, providing direct statistical insights from the CRLs and offering prescriptive, actionable guidance to help development teams navigate the path to approval more effectively.

Chapter 2: The Quantitative Landscape of Submission Deficiencies

A systematic review of the 202 CRLs reveals clear, quantifiable patterns. The tables below provide a granular breakdown of the most common deficiencies cited by the FDA. It is crucial to note that a single CRL often contains multiple deficiencies across different categories.

I. Chemistry, Manufacturing, and Controls (CMC) Deficiencies (Incidence: 74%)

Specific CMC Deficiency	Incidence	Illustrative Quote from a CRL
1. Unresolved Facility Inspection Issues	58%	"During a recent inspection of the...manufacturing facility...our field investigator conveyed deficiencies to the representative of the facility. Satisfactory resolution of these deficiencies is required."
2. Impurity/Degradant Qualification	28%	"You have not provided adequate data to qualify the proposed drug product degradant...which exceeds the ICH Q3B(R2) qualification threshold."
3. Inadequate Process Control Strategy	25%	"The proposed ranges for certain process parameters are unacceptable, given that their values exceed those evaluated during process validation."
4. Insufficient Stability Data	19%	"The proposed 18 month expiration dating period is not supported by the stability data as two out of the six (6) commercial batches...failed."
5. Unvalidated Analytical Methods	17%	"The suitability of proposed assay method...has not been fully demonstrated...the method may be underestimating the amount of [API]."
6. Leachables & Extractables Assessment	15%	"You have not provided adequate validated leachable data to permit a substantive toxicological risk assessment for the proposed container closure system."
7. Clinical vs. Commercial Comparability Gap	13%	"The product used in the clinical studies was manufactured at a different facility than the to-be-marketed product. You have not provided adequate information...to bridge these two products."
8. Container Closure & Compatibility Issues	11%	"Your data demonstrate that the drug product solution is incompatible with the proposed commercial borosilicate glass vials."
9. Inadequate Dissolution/Release Profile	10%	"The proposed dissolution acceptance criterion...is not supported by the provided dissolution data and is not acceptable."
10. Reference Standard Qualification	7%	"The primary reference standard (PRS) was not appropriately qualified with respect to biological activity...and therefore, is not appropriate for its intended use."

II. Clinical & Efficacy Deficiencies (Incidence: 35%)

Specific Clinical Deficiency	Incidence	Illustrative Quote from a CRL
1. Failed Primary Endpoint	16%	"Study...failed to demonstrate superiority of [the drug] for its primary symptom endpoint."
2. Lack of Scientific Bridge (505(b)(2))	12%	"The results of the pharmacokinetic (PK) bridging study...failed to show PK comparability between the...product used in [clinical trials] and the planned commercial product."
3. Small or Unclear Clinical Benefit	9%	"The magnitude of the treatment effect is small and of unclear clinical significance."
4. Insufficient Long-Term Safety Data	8%	"The safety database is insufficient to adequately characterize the long-term safety...Your BLA submission contains data for only 49 patients who were exposed...for 12 months."
5. Flawed Study Design or Analysis	7%	"The analyses of HARMONY I have a number of inadequacies, and we do not regard the study as an adequate and well-controlled trial for the cataplexy endpoint."
6. Unfavorable Benefit-Risk Assessment	6%	"Given the availability of other...therapies that have similar efficacy and that do not carry this risk, [the product] does not appear to address any identifiable unmet need that would justify its approval."
7. Need for Additional Confirmatory Trial(s)	5%	"To address this deficiency, you will need to conduct an additional adequate and well-controlled trial demonstrating a clinically relevant treatment effect."
8. Inadequate Dosing Regimen Justification	4%	"You will need to provide a plan for dosing after one or more missed doses."
9. Data Quality/Integrity Issues at Clinical Sites	3%	"Our review identified investigational product (IP) dosing errors...Because of these data quality issues, the dosing data...cannot be relied upon."
10. REMS Requirement Not Met	2%	"Your application cannot be approved without a REMS; therefore, you must include your proposed REMS to address this deficiency."

III. Device & Human Factors Deficiencies (Incidence: 18%)

Specific Device/HF Deficiency	Incidence	Illustrative Quote from a CRL
1. Human Factors (HF) Validation Failure	14%	"Based on the evaluation of the human factors (HF) study results, the user interface does not support the safe and effective use of the proposed product."
2. Inadequate Device Performance/Reliability	6%	"Provide testing demonstrating that your...needle safety performance...can meet a confidence and reliability of 95%/99% after aging...drop testing and simulated shipping."
3. Inadequate Instructions for Use (IFU)	5%	"Revise the IFU to include instructions for users to inject the medication slowly and steadily."
4. Lack of Data on Final To-Be-Marketed Device	4%	"Your HF study did not evaluate the final intend-to-market user interface...Thus, you have not provided sufficient data to demonstrate whether the intended users can open and close the packaging."
5. Inadequate Device Design or Control Strategy	3%	"Significant variability of the delivered dose, a product critical quality attribute."

The FDA isn't vague - the patterns are crystal clear. Over 70% of CRLs hinge on manufacturing and quality failures, not science. If you know where the landmines are, you can avoid them.

Chapter 3: Deep Dive Analysis: Primary Failure Modes

Finding 3.1: CMC - The Execution Gap

The data overwhelmingly indicates that sponsors are underestimating the complexity and rigor required for the CMC portion of their application. These are not minor issues; they are foundational pillars of a successful submission.

- Facility Compliance is Non-Negotiable (58% of CRLs): The state of the manufacturing facility is not a peripheral concern; it is central to the application. The FDA's language is unambiguous: "Satisfactory resolution of these deficiencies is required before this application may be approved." Our analysis shows that in approximately 90% of these cases, the CRL was a direct result of unresolved "objectionable conditions" found during an inspection. The implication is clear: a sponsor's quality oversight of its supply chain is under direct regulatory scrutiny.

- Product Characterization is a Prerequisite for Safety (41% of CRLs): A significant portion of rejections stemmed from an incomplete understanding of the drug product itself.

    - Impurities & Leachables (28%): Sponsors frequently failed to qualify compounds that exceeded safety thresholds. One letter explicitly states, "You have not provided adequate data to qualify the proposed drug product degradant...which exceeds the ICH Q3B(R2) qualification threshold." This is a critical failure, as it introduces unknown safety risks that cannot be addressed late in the review cycle.

    - Stability (19%): Multiple CRLs cited stability failures, noting that the data provided was insufficient to support the proposed shelf-life. One letter stated the proposed expiration date "is not supported by the stability data as two out of the six (6) commercial batches...failed."

    - Container Compatibility (11%): Several applications were rejected due to physical or chemical incompatibility with the container closure system. One noted, "Your data demonstrate that the drug product solution is incompatible with the proposed commercial borosilicate glass vials."

- Process Control Demonstrates Mastery (33% of CRLs): The FDA requires sponsors to prove they have mastery over their manufacturing process. In a third of cases, sponsors failed to do so. A common theme was setting process parameter ranges that "exceed those evaluated during process validation," indicating a lack of process understanding and control.

Finding 3.2: Clinical - The Evidence Gap

While less frequent than CMC issues, clinical deficiencies (35%) are more fundamental, often requiring new, lengthy, and expensive trials to resolve. The core issue is a failure to provide "substantial evidence of effectiveness."

- Pivotal Trial Failure (16% of CRLs): The most unambiguous reason for a clinical CRL is the failure of a pivotal trial to meet its primary endpoint. This is a direct invalidation of the study's core hypothesis. One CRL stated this clearly: "Study (Trial KPI-121-C-002) failed to demonstrate superiority of loteprednol etabonate ophthalmic suspension, 0.25% for its primary symptom endpoint." This type of deficiency almost invariably requires a new, successful adequate and well-controlled trial.

- The 505(b)(2) Bridging Risk (12% of CRLs): For sponsors using the 505(b)(2) pathway, establishing a "scientific bridge" to the reference drug is a critical risk point. The most common failure is in demonstrating pharmacokinetic (PK) equivalence. One letter stated, "The results of the pharmacokinetic (PK) bridging study...failed to show PK comparability between the...product used in [clinical trials] and the planned commercial product." This severs the link to the reference drug's established safety and efficacy data, invalidating a key premise of the application and often requiring significant reformulation or new clinical work.

- The Question of Clinical Relevance (9% of CRLs): A more nuanced but equally fatal flaw is achieving statistical significance on an endpoint that the FDA does not find clinically meaningful. In these cases, the sponsor proved their hypothesis, but the agency was not convinced the result mattered to patients. One CRL noted, "...the magnitude of the treatment effect is small and of unclear clinical significance." This highlights a critical strategic failure: a misalignment between the sponsor and the FDA on what constitutes a valuable therapeutic benefit.

- Insufficient Long-Term Safety Data (8% of CRLs): For drugs intended for chronic use, the FDA has clear expectations for the duration of safety follow-up. Several CRLs were issued because the safety database was too small or too short. One letter stated, "The safety database is insufficient to adequately characterize the long-term safety...Your BLA submission contains data for only 49 patients who were exposed...for 12 months," when the expectation was for at least 100 patients.

A statistically significant result isn't enough. If the FDA doesn't see meaningful clinical benefit, your trial fails - regardless of the p-value.

Finding 3.3: Device & Human Factors - The Integration Gap

For the 18% of CRLs involving a combination product, the device is not an accessory—it is the drug. The analysis shows a clear trend of failures in this area, where sponsors treat the device and its usability as a secondary concern.

- Human Factors Validation is Pivotal (14% of CRLs): The most common device-related failure was an unsuccessful HF validation study. The FDA's language is direct and leaves no room for interpretation: "Based on the evaluation of the human factors (HF) study results, the user interface does not support the safe and effective use of the proposed product." These failures were not minor. They often involved use errors on critical tasks that could lead to significant patient harm, such as under-dosing, over-dosing, or accidental exposure.

- Inadequate Device Performance & Reliability (6% of CRLs): Beyond usability, the physical performance of the device itself was a cause for rejection. These issues often surfaced during stability testing or were related to the manufacturing process. One CRL cited "Significant variability of the delivered dose," while another required the sponsor to "Provide testing demonstrating that your…needle safety performance…can meet a confidence and reliability of 95%/99% after aging…drop testing and simulated shipping." This demonstrates that the FDA expects the device to perform reliably under real-world conditions and throughout its entire shelf-life.

- Lack of Data on the Final Device (4% of CRLs): In several cases, sponsors conducted HF or performance testing on a device that was not the final, to-be-marketed version. This invalidates the data. One CRL noted, "Your HF study did not evaluate the final intend-to-market user interface…Thus, you have not provided sufficient data to demonstrate whether the intended users can open and close the packaging."

The device in a combination product is not an accessory - it's integral to the therapy itself. The FDA doesn't treat usability as a formality. If patients can't use it safely and effectively, the entire product fails. A flawed Human Factors study carries the same regulatory weight as a failed Phase 3 trial.

Chapter 4: Modality-Specific Failure Patterns

ProGen Search's analysis segmented the CRLs by therapeutic modality to identify unique risk profiles. This provides a more granular view of the challenges facing different areas of drug development.

Biologics & Biosimilars (Approx. 45% of Analyzed CRLs)

For biologics, the complexity of the molecule and its manufacturing process creates a distinct set of challenges.

- **Top Failure Reason:** Facility Compliance (65% of Biologic CRLs). The intricate nature of biologics manufacturing, particularly aseptic processing, makes facility compliance the number one hurdle. Deficiencies related to sterility assurance, environmental monitoring, and process validation were paramount.
- **Key Challenge:** Analytical Comparability. For biosimilars, a significant number of CRLs (~20% of this subgroup) cited a failure to demonstrate analytical similarity to the reference product. Issues with assays for potency, glycosylation, and charge variants were common. One CRL noted, "The CEX-HPLC analytical similarity data indicate differences in charge variants between [the proposed product] and US-licensed [reference product]."
- **Immunogenicity Assay Validation:** A recurring theme was the inadequacy of the immunogenicity assays. One letter detailed extensive deficiencies, stating, "Both NAb [neutralizing antibody] assays, are inadequate...and will not allow for meaningful evaluation of NAb in clinical samples."

Strategic Implication: For biologics sponsors, the primary focus must be on manufacturing excellence and analytical rigor. The data suggests that investment in state-of-the-art facilities, robust quality systems, and highly sensitive, well-validated analytical methods is not optional—it is the price of entry.

In biologics, the science may be sound - but it's manufacturing precision and analytical depth that determine success.

Without robust systems and validated assays, even the most promising molecule won't make it past the finish line.



Small Molecules (Approx. 40% of Analyzed CRLs)

For small molecule drugs, the focus of FDA scrutiny shifts from the manufacturing process to the final drug product's characteristics and its interaction with the container closure system.

- **Top Failure Reason:** Leachables & Impurities (45% of Small Molecule CRLs). This was the most significant challenge for small molecule developers. The FDA consistently rejected applications due to a failure to fully identify, characterize, and qualify leachables from stoppers, vials, and other packaging components. One CRL stated, "You have not adequately qualified the safety of the identified leachables detected with your drug product."
- **Key Challenge:** Inadequate Dissolution/Release Profile. A substantial number of rejections (~25% of this subgroup) were due to unacceptable dissolution specifications or high variability in drug release. One CRL noted, "The provided in vitro drug release testing (IVRT) data...show high inter-batch and intra-batch variabilities."
- **The 505(b)(2) Bridge:** Similar to biologics, establishing a scientific bridge was a key hurdle, with ~15% of small molecule CRLs citing a failure to demonstrate pharmacokinetic equivalence to the listed drug.

Strategic Implication: For small molecule sponsors, the container is as critical as the contents. An exhaustive understanding of all potential leachables and a robust, discriminating dissolution method are essential. ProGen Search recommends that leachables studies be initiated as soon as the final packaging is selected to avoid late-cycle surprises.

If you don't fully understand how your formulation behaves in its final container, the FDA will assume the worst - and act accordingly.

Combination Products & Devices (Approx. 15% of Analyzed CRLs)

For products involving a device, the CRLs show that the FDA views the drug and device as a single, integrated system. A failure in one component is a failure of the entire product.

- **Top Failure Reason:** Human Factors & Usability (78% of Device-related CRLs). This was the overwhelming reason for rejection in this category. Sponsors repeatedly failed to demonstrate that intended users could use the device safely and effectively. One letter was blunt: "The results of the HF validation study demonstrated several use errors/close calls/use difficulties with critical tasks that may result in harm to the patient."

- **Key Challenge:** Device Performance & Reliability. Issues with the physical performance of the device, such as dose accuracy, needle safety feature activation, and container closure integrity after assembly, were also significant contributors.

Strategic Implication: Sponsors of combination products must abandon a drug-centric development model. The device's design, usability, and reliability must be treated as co-equal, pivotal development streams. ProGen Search's analysis strongly suggests that a failed HF study should be viewed with the same gravity as a failed Phase 3 trial, as it almost guarantees a CRL

In the eyes of the FDA, a combination product is a single therapeutic system. If the user can’t safely and reliably operate the device, it doesn’t matter how well the drug works - the entire product fails.

Chapter 5: ProGen Search Recommendations - Strategic Imperatives & Role-Specific Action Plans

To mitigate the risks identified in this analysis, sponsors must embed a culture of regulatory and operational excellence early in the development lifecycle. The following role-specific action plans provide a framework for proactive risk management.

Checklist for the Head of CMC / Technical Operations

Focus Area: Bridging the gap between development-scale science and commercial-scale, compliant manufacturing. The data indicates that 74% of all CRLs involve major CMC deficiencies.

- **[ ] Mandate a Formal Process "Lock-Down" Pre-Pivotal Trial.**
  - **Insight:** 13% of CRLs cited a failure to bridge the clinical trial product with the to-be-marketed commercial product due to process changes.
  - **Action:** Implement a formal stage-gate review before the manufacture of pivotal clinical trial material. This review must confirm that the manufacturing process, formulation, and primary container closure system are finalized. Any post-pivotal change must trigger a formal, documented comparability assessment and a regulatory risk evaluation
- **[ ] Initiate Extractable & Leachable (E&L) Studies at Container Selection.**
  - **Insight:** 15% of CRLs cited an inadequate E&L assessment, often because studies were incomplete at the time of submission.
  - **Action:** Do not wait for registration stability batches. The E&L program must be initiated as soon as the final container closure system and all product-contact manufacturing components are identified. This provides the necessary time to fully characterize and toxicologically qualify any compounds of concern.
- **[ ] Establish and Enforce a "Zero-Tolerance" OOS/OOT Culture.**
  - **Insight:** 19% of CRLs cited insufficient stability data, often complicated by out-of-specification (OOS) or out-of-trend (OOT) results that were inadequately investigated.
  - **Action:** Implement a formal Stability Review Committee that meets quarterly. Every OOS/OOT result must trigger a full, phase-appropriate root cause investigation. A simple "re-test and pass" is insufficient; the investigation must be scientifically sound and documented for the submission.
- **[ ] Validate All Critical Analytical Methods Before Registration Batches are Made.**
  - **Insight:** 17% of CRLs cited unvalidated or inadequately validated analytical methods used for product release and stability testing.
  - **Action:** Ensure that all methods for critical quality attributes (CQAs)—especially for potency, purity, and impurities—are fully validated per ICH Q2(R1) guidelines before the first registration stability batch is manufactured. This includes robustness testing to ensure the method performs reliably across different labs, analysts, and equipment.

The FDA doesn’t approve development-stage thinking. If your commercial process isn’t locked, validated, and inspection-ready by submission, you’re not just taking a risk - you’re planning for a rejection.

Checklist for the VP of Regulatory Affairs

Focus Area: Proactive agency engagement and ensuring the submission tells a single, cohesive story. The goal is to eliminate regulatory surprises.

- **[ ] Secure Early Alignment on Clinically Meaningful Endpoints.**
  - **Insight:** 9% of CRLs were issued because the FDA deemed the treatment effect "small or of unclear clinical significance," even when the primary endpoint was met statistically.
  - **Action:** Drive the cross-functional team to secure FDA agreement on what constitutes a clinically meaningful benefit at the End-of-Phase 2 meeting. This agreement must be clearly documented in meeting minutes and serve as the foundation for the Phase 3 statistical analysis plan.
- **[ ] De-Risk the 505(b)(2) Bridging Strategy.**
  - **Insight:** 12% of CRLs cited a failure to establish a scientific bridge to the listed drug, most often due to pharmacokinetic (PK) differences.
  - **Action:** If pursuing a 505(b)(2) pathway, the PK bridging study is a pivotal, high-risk milestone. The regulatory strategy must include contingency plans (e.g., reformulation, additional clinical work) in the event the bridge fails to meet conventional bioequivalence criteria.
- **[ ] Integrate the Pre-Approval Inspection (PAI) Plan into the Submission Timeline.**
  - **Insight:** 58% of CRLs cited facility inspection issues. This is not just a Quality/CMC issue; it is a critical regulatory risk.
  - **Action:** The regulatory timeline must account for PAI readiness. Confirm with the Head of Quality that all critical domestic and foreign manufacturing sites have been audited and are inspection-ready before filing. Any unresolved Form 483s at a listed facility should be considered a high-risk item for the submission.
- **[ ] Conduct a Pre-Submission "Murder Board" Review.**
  - **Insight:** CRLs frequently cite inconsistencies across different sections of the application (e.g., between the manufacturing description and the stability plan).
  - **Action:** Before filing, convene a cross-functional team of internal or external experts who were not involved in writing the submission. Their sole task is to critically review the entire application for inconsistencies, gaps, and weaknesses, simulating an FDA review.

Regulatory success isn't just about good science - it's about telling a clear, consistent story the FDA can trust. Misalignment, missing data, or a weak scientific bridge aren't small gaps - they're where approvals fall apart.

Checklist for the Chief Medical Officer (Clinical)

Focus Area: Ensuring the clinical data package is robust, interpretable, and sufficient to support a favorable benefit-risk assessment.

- **[ ] Validate the Primary Endpoint Before Phase 3.**
    - **Insight:** 16% of CRLs were due to a failed primary endpoint.
    - **Action:** Ensure that the primary endpoint for the pivotal trial(s) has been thoroughly vetted for clinical relevance with key opinion leaders and, most importantly, has been discussed and agreed upon with the FDA. The study must be powered to detect a pre-specified, clinically meaningful effect on this endpoint.
- **[ ] Mandate ICH E1A-Compliant Long-Term Safety Exposure.**
    - **Insight:** 8% of CRLs cited an insufficient long-term safety database for products intended for chronic or intermittent long-term use.
    - **Action:** For any such product, the clinical development plan must prospectively include a cohort of at least 100 patients treated for 12 months to satisfy regulatory expectations for characterizing long-term safety.
- **[ ] Proactively Manage the Benefit-Risk Narrative.**
    - **Insight:** 6% of CRLs concluded the benefit-risk profile was unfavorable, often due to safety signals that emerged during development.
    - **Action:** Establish a Safety Management Committee that not only monitors adverse events but is also responsible for continuously updating the product's benefit-risk assessment. If a new risk emerges, the team must be prepared to provide a comprehensive analysis and a risk mitigation plan (e.g., a REMS proposal) in the NDA.

Meeting your endpoint isn’t the finish line - it’s just the start of FDA scrutiny. Success comes when your data tells a story of meaningful benefit, long-term safety, and a risk profile you’ve already planned to defend.

Checklist for the Head of Quality / GMP Compliance

Focus Area: Ensuring a state of constant inspection readiness and data integrity across the entire supply chain.

- **[ ] Implement a Proactive CMO Audit Program.**
  - **Insight:** 58% of CRLs cited facility inspection failures, making this the single largest cause of rejection.
  - **Action:** Do not rely on paper-based audits or vendor qualification questionnaires. Conduct rigorous, on-site GMP audits of all critical contract manufacturing and testing facilities. These audits must verify that the facility's quality system is effective and that any prior regulatory observations have been resolved.
- **[ ] Stress-Test the Quality System for Data Integrity.**
  - **Insight:** Several CRLs cited a lack of data reliability discovered during an inspection, which can invalidate key sections of a submission.
  - **Action:** Conduct internal data integrity audits focused on high-risk areas: analytical laboratory data (ensuring no "testing into compliance"), batch records (ensuring all deviations are documented and investigated), and stability programs.
- **[ ] Ensure Quality Agreements are Specific and Enforceable.**
  - **Action:** Review all Quality Agreements with CMOs. They must explicitly define responsibilities for key activities such as OOS investigations, change control, deviation management, and regulatory inspection support. Vague agreements lead to critical gaps in oversight.
- **[ ] Mandate a Formal PAI Readiness Plan for Every Site.**
  - **Action:** Each manufacturing site must have a documented PAI readiness plan. This plan should include designated subject matter experts for key processes, a "back room" support team, and a clear communication cascade for managing an inspection. This plan should be rehearsed via mock inspections.

Quality isn’t what you write in a SOP - it’s what the FDA sees when they walk through the door. If your sites aren’t inspection-ready and your data can’t withstand scrutiny, your submission doesn’t stand a chance.

ProGen Search

Are You FDA Ready?

ProGen Search now offers two ways to de-risk your regulatory roadmap and build the team to deliver it.

RedFlag - Strategic FDA Submission Intelligence

Get a bespoke RedFlag analysis that matches your program against 202 FDA rejections to surface hidden risk patterns early.

Whether you're preparing for IND, BLA, or NDA submission, RedFlag uncovers critical weak points before they trigger a CRL - so you know what to fix, and who to hire to fix it.

- Match your asset to failed programs with similar modality, delivery route, or failure mode
- Understand how CRLs in your space are trending
- Convert FDA failure data into actionable strategy

Click here to request a RedFlag Report.

Executive Hiring - Scale With Confidence

From FDA readiness to commercial launch, ProGen Search helps you hire the right talent to make regulatory success a reality. Whether you're looking for:

- VP of Regulatory Affairs
- Head of Quality / CMC
- Technical Operations Leadership
- Clinical Development Expertise

We bring the network, the insight, and the execution to deliver.

Click here to book a Hiring Strategy Call.